REGN logo

Regeneron Pharmaceuticals, Inc.

REGN
Healthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46

Clinical Trials (511)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT06665971
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE)
P4
Recruiting30Open-labelDupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
NCT07142343
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
CHAPLE Disease
P4
Recruiting5Open-labelPozelimab
NCT05983068
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
Dermatitis Atopic
P4
Active48Open-labeldupilumab
NCT06352073
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
Eosinophilic Esophagitis, EoE
P4
Active23Open-labelDupilumab
NCT05042258
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Atopic Dermatitis, Sleep Disturbance
P4
Recruiting40Open-labelDupilumab
NCT06662994
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Diabetic Macular Edema (DME)
P4
Recruiting15Open-labelAflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
NCT03935971
The Effects of Dupilumab on Allergic Contact Dermatitis
Allergic Contact Dermatitis
P4
Active17Open-labelDupilumab
NCT07053423
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease
P4
Recruiting218RCT, Double-blindDupilumab, Placebo
NCT05097287
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Asthma
P4
Active1,339RCT, Double-blindDupilumab, Placebo
NCT07587658
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
Chronic Obstructive Pulmonary Disease (COPD)
P4
Recruiting754RCT, Double-blinddupilumab, Placebo
NCT04380038
Viral Infection in Asthma (VIA) Study
Asthma
P4
Recruiting60RCT, Double-blindDupilumab Injectable Product
NCT05268107
Ethnic Differences in Mechanisms of Action of Dupilumab
Atopic Dermatitis
P4
Recruiting30Open-labelDupilumab
NCT07609940
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Relapsed/Refractory Multiple Myeloma (RRMM)
P4
Recruiting30Open-labelLinvoseltamab, Tocilizumab
NCT05352672
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Melanoma
P3
Active1,546RCT, Double-blindFianlimab, Cemiplimab, Pembrolizumab, Placebo
NCT06230224
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin Lymphoma (B-NHL)
P3
Active216RCT, Open-labelOdronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine
NCT05991388
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
P2P3
Recruiting210Open-labelOdronextamab, Loncastuximab tesirine, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC)
NCT07424144
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
P3
Active59RCT, Double-blindItepekimab (SAR440340), Placebo
NCT05800015
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
P2P3
Active160RCT, Double-blindfianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
NCT07318610
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
P3
Recruiting7,050RCT, Double-blindREGN7508, REGN9933, Placebo, Rivaroxaban
NCT05785767
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
P2P3
Active149RCT, Double-blindfianlimab, cemiplimab, Placebo
NCT06091254
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma (FL)
P3
Recruiting822RCT, Open-labelOdronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine
NCT06293053
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Prurigo Nodularis
P3
Recruiting18Open-labelDupilumab
NCT05608291
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Melanoma
P3
Active1,564RCT, Double-blindFianlimab, Cemiplimab, Pembrolizumab, Placebo
NCT06149286
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
P3
Recruiting580RCT, Open-labelOdronextamab, Lenalidomide, Rituximab
NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Multiple Myeloma
P3
Recruiting1,000RCT, Open-labelLinvoseltamab, Daratumumab, Lenalidomide, Dexamethasone
NCT06091865
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
P3
Recruiting904RCT, Open-labelOdronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
NCT07220785
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
P3
Recruiting28RCT, Double-blindMibavademab, Placebo
NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
P3
Recruiting1,200RCT, Double-blindNTLA-2001, Placebo
NCT06585410
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (CSCC)
P3
Recruiting369RCT, Open-labelCemiplimab
NCT06541704
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
P3
Recruiting975RCT, Double-blindPozelimab, Cemdisiran, Placebo
NCT07854782
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
P3
Recruiting1,500RCT, Double-blindALN-CIDEB, Placebo
NCT07154745
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Paroxysmal Nocturnal Hemoglobinuria
P3
Recruiting35Open-labelPozelimab, Cemdisiran
NCT06931717
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Non-Small Cell Lung Cancer
P3
Recruiting390RCT, Open-labelCemiplimab
NCT07220772
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
Monogenic Obesity
P3
Recruiting4Open-labelMibavademab
NCT03480568
Alirocumab in Patients on a Stable Dialysis Regimen
Hemodialysis, Peritoneal Dialysis
P3
Recruiting20Open-labelAlirocumab 150 MG/ML [Praluent]
NCT07697599
Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
Venous Thromboembolism (VTE)
P3
Recruiting1,908RCT, Double-blindREGN7508, REGN9933, Placebo
NCT03969004
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
P3
Active415RCT, Double-blindCemiplimab, Placebo
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
P3
Recruiting410RCT, Open-labelLinvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone
NCT07430956
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Atrial Fibrillation (AF)
P3
Recruiting2,628RCT, Double-blindREGN7508, REGN9933, Placebo
NCT07309614
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
P3
Recruiting150RCT, Double-blindDupilumab Prefilled Syringe, Placebo Injection
NCT06491914
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
P3
Active1,126Open-labelAflibercept 8 mg
NCT06834347
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
P3
Active231RCT, Double-blindItepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
NCT06834360
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
P3
Active216RCT, Double-blindItepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
NCT07493304
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
P3
Recruiting1,600RCT, Open-labelREGN7508, Apixaban
NCT06672237
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Neuromuscular Disease, Neuromuscular Diseases (NMD)
P3
Active67RCT, Double-blindnexiguran ziclumeran, Normal Saline as Placebo
NCT06246916
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
P3
Recruiting560RCT, Open-labelfianlimab, cemiplimab, relatlimab+nivolumab
NCT07675811
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
Allergic Conjunctivitis
P3
Recruiting570RCT, Double-blindREGN-2Cat, Freneslerbart, Mevonlerbart, Placebo
NCT07410117
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
P3
Recruiting1,120RCT, Double-blindREGN7508, Placebo
NCT07626411
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
P3
Recruiting15,364RCT, Double-blindREGN7508, Apixaban, Placebo
NCT04050436
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
P2
Active231RCT, Open-labelCemiplimab, RP1
NCT04291105
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Melanoma, Head and Neck Squamous Cell Carcinoma
P2
Active87Open-labelVV1, Cemiplimab
NCT05347771
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Asthma
P2
Active240RCT, Double-blindDupilumab, Placebo
NCT07058012
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Colo-rectal Cancer
P2
Recruiting79Open-labelCemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075
NCT06444880
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
P2
Active15Open-labelUbamatamab, Cemiplimab
NCT07431086
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
Overweight or Obesity
P2
Active120RCT, Double-blindOlatorepatide, Placebo
NCT06190951
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Melanoma
P2
Active151RCT, Double-blindcemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
NCT07455851
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
P1P2
Recruiting150Open-labelLinvoseltamab, REGN17372+Linvoseltamab
NCT04626635
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Advanced Solid Tumors
P1P2
Active548Open-labelREGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
NCT06449313
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Non-small Cell Lung Cancer Stage III
P2
Recruiting21Open-labelCemiplimab-Rwlc
NCT05553834
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Non-small Cell Lung Cancer (NSCLC)
P2
Active60Open-label—
NCT07187401
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
P1P2
Recruiting24RCT, Double-blindALN-CFB, Placebo
NCT07746388
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
Nsclc, NSCLC Stage II
P2
Recruiting30Open-labelCemiplimab
NCT05828511
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
P1P2
Active148Open-labelLinvoseltamab
NCT06918132
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8
P2
Recruiting60Open-labelCemiplimab, Fianlimab
NCT07281768
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Colorectal Cancer
P2
Recruiting66RCT, Open-labelOxaliplatin, Capecitabine, Cemiplimab, Fianlimab, REGN7075
NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Relapsed/Refractory Systemic Light Chain Amyloidosis
P1P2
Recruiting220Open-labelLinvoseltamab
NCT06981325
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Basal Cell Carcinoma (BCC), First Line Treatment
P2
Recruiting34Open-labelCemiplimab
NCT07154290
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
P2
Recruiting300RCT, Open-labelUbamatamab, Marlotamig, Sarilumab
NCT06651593
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Solid Tumors
P2
Recruiting40Open-labelSAR444881, Cemiplimab
NCT06887088
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
P2
Recruiting33Open-labelEncorafenib + Binimetinib, cemiplimab+fianlimab
NCT05125016
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
P1P2
Recruiting228Open-labelREGN4336, REGN5678
NCT07175428
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
P2
Recruiting1,200RCT, Single-blindREGN7508, REGN9933, Apixaban
NCT06226610
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Pruritis
P2
Recruiting46RCT, Double-blindDupilumab
NCT07631637
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
P2
Recruiting150RCT, Double-blindALN-CIDEB, Placebo
NCT07675824
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
P1P2
Recruiting271RCT, Double-blindREGN22530
NCT07234058
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Pleural Mesotheliomas
P2
Recruiting126RCT, Open-labelCemiplimab, Fianlimab, Pemetrexed (Alimta), Cisplatin, Carboplatin (AUC 5)
NCT06910124
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Multiple Myeloma
P2
Recruiting32Open-labelLinvoseltamab, Lenalidomide
NCT06865339
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
NSCLC, Locally Advanced
P2
Recruiting76Open-labelCemiplimab, Fianlimab, Platinum Doublet Chemotherapy (PDC)
NCT05519475
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
P2
Recruiting120RCT, Double-blindALN-HSD, Placebo
NCT03951831
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Prostate Cancer Metastatic
P2
Active26Open-labelREGN2810, Degarelix, Leuprolide Acetate, Docetaxel
NCT02991469
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Juvenile Idiopathic Arthritis
P2
Recruiting51Open-labelSarilumab SAR153191 (REGN88)
NCT07251413
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Cutaneous Basal Cell Carcinoma
P1P2
Recruiting18RCT, Open-labelcemiplimab, Topical imiquimod
NCT03888105
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
B-cell Non-Hodgkin Lymphoma (B-NHL)
P2
Active515Open-labelOdronextamab
NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
P1P2
Recruiting387Open-labelLinvoseltamab
NCT06385262
TOP 2301: Neoadjuvant Chemo for NSCLC
Non Small Cell Lung Cancer
P2
Recruiting63Open-labelAlirocumab, Cemiplimab, Chemotherapy
NCT05720325
Dupilumab Effects Against Aeroallergen Challenge
Asthma, Allergic
P2
Active96RCT, Double-blindDupilumab
NCT05878288
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
P2
Active11Open-labelCemiplimab
NCT07704580
Phase 1b/2 Study of IV Sarilumab in Adult With RA
Rheumatoid Arthritis
P1P2
Recruiting140RCT, Open-labelSarilumab, SAR153191 SC, Sarilumab, SAR153191 IV
NCT07223541
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
P2
Recruiting72RCT, Open-labelCemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
NCT06769698
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
P2
Recruiting120RCT, Double-blindFDC fianlimab+cemiplimab, Cemiplimab, Placebo
NCT06669247
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
P1P2
Recruiting186Open-labelLinvoseltamab, REGN7945+Linvoseltamab
NCT06787612
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
P2
Recruiting397RCT, Open-labelUbamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
NCT06421636
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
P2
Active19RCT, Double-blindREGN7999, Placebo
NCT04989946
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
Prostate Cancer
P1P2
Active57RCT, Open-labelDegarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
NCT05955508
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Smoldering Multiple Myeloma (SMM)
P2
Active40RCT, Open-labelLinvoseltamab
NCT07685808
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Overweight or Obesity
P2
Recruiting360RCT, Double-blindOlatorepatide, Placebo
NCT07235917
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Functional Hypothalamic Amenorrhea, FHA
P2
Recruiting34RCT, Double-blindMibavademab
NCT05551793
Regeneron AA Multicenter (Dupilumab)
Alopecia Areata
P2
Recruiting76RCT, Double-blindDupilumab, Placebo
NCT07527910
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
P2
Recruiting204RCT, Double-blindALN-PNP, Tirzepatide, Placebo
NCT06448026
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
P2
Recruiting17Open-labelCemiplimab, Cetuximab
NCT06623656
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Carcinoma, Non-Small-Cell Lung
P2
Recruiting112RCT, Open-labelCemiplimab, Platinum based chemotherapy
NCT06351592
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
P1P2
Recruiting54RCT, Open-labelALN-SOD, Placebo (PB)
NCT07188896
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC)
P2
Recruiting120RCT, Open-labelFianlimab, Ipilimumab, Nivolumab, Cemiplimab
NCT06836609
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
P1P2
Active118RCT, Double-blindALN-CIDEB, Placebo
NCT05557591
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Advanced Non-Small Cell Lung Cancer
P2
Active51RCT, Open-labelBNT116, Cemiplimab
NCT07271186
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
P2
Recruiting195RCT, Double-blindALN-ANG3, Evinacumab, Placebo
NCT05648214
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
P1P2
Recruiting172RCT, Double-blindALN-PNP, Placebo (PB)
NCT05961709
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Colon Cancer
P2
Active50Open-labelCemiplimab
NCT03564340
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
P1P2
Recruiting890Open-labelUbamatamab, Cemiplimab, Sarilumab, Tocilizumab
NCT06299098
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Obesity
P2
Active1,005RCT, Double-blindTrevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab
NCT06161441
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Resectable Non-small Cell Lung Cancer
P2
Active195RCT, Double-blindFianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
NCT06855212
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Head and Neck Squamous Cell Carcinoma
P2
Active22Open-labelCemiplimab, Cetuximab
NCT07214727
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Alzheimer's Disease
P1
Recruiting50RCT, Double-blindALN-5288, Placebo
NCT07753148
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS)
P1
Recruiting52Open-labelREGN17235
NCT06902376
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Anaplastic Thyroid Cancer, Thyroid Cancer
P1
Recruiting12Open-labelCemiplimab, XL092
NCT05685173
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
B-cell Non-Hodgkins Lymphoma (B-NHL)
P1
Recruiting107Open-labelOdronextamab, REGN5837
NCT07527923
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
P1
Recruiting160RCT, Double-blindREGN20423
NCT05105152
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
P1
Recruiting18Open-labelSC-DARIC33
NCT07230834
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Geographic Atrophy (GA)
P1
Recruiting54RCT, Double-blindPozelimab
NCT03233139
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Advanced Malignancies
P1
Active146Open-labelCemiplimab, Ipilimumab, Platinum-doublet chemotherapy, Gemcitabine, Pemetrexed, Paclitaxel, Fianlimab
NCT04722523
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Head and Neck Cancer, Head Cancer
P1
Recruiting40Open-labelCisplatin, Carboplatin, Docetaxel, Cetuximab, Cemiplimab, Paclitaxel
NCT07594093
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Overweight or Obesity
P1
Recruiting90RCT, Double-blindREGN20934, Placebo
NCT07526116
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
Healthy Volunteer
P1
Recruiting88RCT, Double-blindREGN22044, Placebo
NCT07543055
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Prostate Cancer
P1
Recruiting36Open-label—
NCT06469281
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
P1
Recruiting90Open-labelCemiplimab, Bevacizumab
NCT05704634
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Lung Cancer
P1
Active56RCT, Open-labelCemiplimab, Kevzara (Sarilumab)
NCT06452771
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
Healthy Volunteers With Hyperlipidemia
P1
Active59RCT, Double-blindALN-ANG3, Placebo (PB)
NCT07759167
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
End-Stage Kidney Disease (ESKD)
P1
Recruiting36RCT, Double-blindREGN9933, REGN7508, REGN9533, Heparin
NCT07118306
COPD Exacerbation Follow Up
COPD (Chronic Obstructive Pulmonary Disease)
Recruiting485——
NCT07444203
Transformative Research in Diabetic Nephropathy 2.0
Diabetic Nephropathies, Kidney Diseases
Recruiting200—Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
NCT02622581
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Recruiting14,500——
NCT05568459
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Hemophilia B
Active11——
NCT06479863
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Early P1
Recruiting10Open-label—
NCT06192563
A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
Atopic Dermatitis
Recruiting230—Dupilumab
NCT06798298
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
Long Term Safety Following GM T Cell Therapy
Recruiting50——
NCT00707694
The Longevity Genes in Founder Populations Project
Extreme Longevity
Recruiting2,000——
NCT06773897
Rutgers University Study of the Genetics of Breast Cancer.
Breast Cancer Risk, Breast Cancer Prevention
Recruiting25,000——
NCT04959448
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Chronic Rhinosinusitis With Nasal Polyposis
Active717—DUPIXENT®
NCT05246267
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis With Nasal Polyps
Active60—Dupilumab
NCT07064330
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Cutaneous Squamous Cell Carcinoma (CSCC)
Recruiting30—Cemiplimab
NCT07606508
Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.
Cutaneous Squamous Cell Carcinoma (CSCC)
Recruiting1,500—Systemic treatment
NCT06415175
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
Atopic Dermatitis
Active143—Dupilumab
NCT07217535
Rutgers University Study of the Genetics of Kidney Disease
Kidney Disease, Kidney Disease, Chronic
Recruiting50,000——
NCT06695897
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
Eosinophilic Esophagitis
Recruiting150—Dupilumab
NCT06169527
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
Atopic Dermatitis
Active303—Dupilumab
NCT07223411
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Locally Advanced Melanoma
Recruiting20—Fianlimab + Cemiplimab, Relatlimab + Nivolumab
NCT03992417
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Dermatitis Atopic
Active955—Dupilumab SAR231893 (REGN668)
NCT00381121
University of Michigan "Nephrology Research BioBank"
Chronic Kidney Disease
Recruiting420——
NCT03428646
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
Dermatitis, Atopic
Active858—Dupilumab
NCT03389893
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
Atopic Dermatitis (AD)
P4
Terminated72RCT, Double-blindDupilumab, Placebo
NCT05049122
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
Chronic Rhinosinusitis With Nasal Polyps
P4
Completed25Open-labelDupilumab SAR231893
NCT02120950
Aflibercept in Polypoidal Choroidal Vasculopathy
Neovascular Macular Degeneration
P4
Completed333RCT, Double-blindAflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT01543568
Study for Recalcitrant Age Related Macular Degeneration
Age Related Macular Degeneration
P4
Completed46Open-labelaflibercept 2.0 mg
NCT07187089
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
Severe Atopic Dermatitis (AD)
P4
Withdrawn—Open-labeldupilumab
NCT04502862
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
Asthma
P4
Completed202RCT, Double-blindSAR231893, Placebo
NCT03468296
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
Neovascular Age-related Macular Degeneration
P4
Unknown22RCT, Open-labelIntravitreal Aflibercept Injection 2mg
NCT01870427
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
Macular Edema With Central Retinal Vein Occlusions
P4
Completed20Open-labelAflibercept (2.0 mg)
NCT04998604
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Chronic Rhinosinusitis With Nasal Polyps, Asthma
P4
Completed360RCT, Double-blindDupilumab, Omalizumab, Placebo
NCT01670162
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
Age Related Macular Degeneration, Pigment Epithelial Detachment
P4
Unknown30Open-labelAflibercept
NCT04718870
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Dermatitis Atopic
P4
Completed41Open-labelDupilumab SAR231893
NCT04823130
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Dermatitis Atopic
P4
Completed54Open-labelDupilumab (SAR231893)
NCT05265234
Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.
Eczema, Atopic Dermatitis
P4
Unknown15Open-labelDupilumab
NCT03542110
The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Saphenous Vein Graft Atherosclerosis
P4
Terminated46RCT, Double-blindAlirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection
NCT04447417
Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Atopic Dermatitis
P4
Completed52Open-labelDupilumab SAR231893
NCT02299336
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
Diabetic Macular Edema
P4
Completed60Open-labelAflibercept
NCT03667014
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
Atopic Dermatitis, Atopic Dermatitis Eczema
P4
Completed34Open-labelDupilumab
NCT04988022
Dupilumab in the Treatment of Keloids
Keloid
P4
Completed44RCT, Double-blindDupilumab, Placebo
NCT01617148
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
Exudative Macular Degeneration
P4
Completed26Open-labelAflibercept
NCT03022292
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
Wet Macular Degeneration
P4
Completed26Open-labelAflibercept Ophthalmic
NCT02689518
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Macular Degeneration, Wet Macular Degeneration
P4
Completed50Open-labelIntravitreal aflibercept injection
NCT05036733
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
Asthma
P4
Completed15Open-labelDupilumab
NCT02305238
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Wet Macular Degeneration
P4
Completed288RCT, Open-labelAflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT05590585
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
P4
Completed124Open-labeldupilumab
NCT01857544
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
Retinal Vein Occlusion
P4
Unknown10Open-labelAflibercept
NCT02581891
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Macular Degeneration
P4
Completed287RCT, Open-labelEylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321), Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
NCT06591598
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
P4
Completed51Open-labelAflibercept (BAY86-5321, Eylea)
NCT06012448
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
Dermal Hypersensitivity Reaction
P4
Completed10Open-labelDupilumab
NCT04520308
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
Atopic Dermatitis, AD
P4
Unknown45Open-labelDupilumab Only Product
NCT03694197
Long Term Safety Study of PRALUENT
Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia
P4
Terminated1,389Open-labelPraluent
NCT03293030
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
Atopic Dermatitis, Atopic Dermatitis Eczema
P4
Completed17Open-labelDupilumab
NCT04400318
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Asthma
P4
Completed109RCT, Double-blindDupilumab, Placebo
NCT04708145
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
Diabetic Retinopathy
P4
Completed41RCT, Open-labelAflibercept Injection
NCT01627249
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Diabetic Macular Edema
P3
Completed660RCT, Single-blind2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
NCT00561470
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Colorectal Neoplasms, Neoplasm Metastasis
P3
Completed1,226RCT, Double-blindPlacebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
NCT02325791
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Respiratory Syncytial Virus Infections
P3
Completed1,177RCT, Double-blindSuptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
NCT01730040
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
Hypercholesterolemia
P3
Completed355RCT, Double-blindAlirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
NCT04417894
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Moderate to Severe Atopic Hand and Foot Dermatitis
P3
Completed133RCT, Double-blinddupilumab, Placebo
NCT03285646
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
Chronic Low Back Pain, Osteoarthritis
P3
Terminated63RCT, Double-blindFasinumab, Placebo
NCT02898454
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
P3
Completed448RCT, Double-blindDupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
NCT00829829
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Intercritical Gout
P3
Completed241RCT, Double-blindRilonacept 80 mg, Rilonacept 160 mg
NCT07901725
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
P3
Not Yet Recruiting382RCT, Open-labelLinvoseltamab, Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone
NCT01709500
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
Heterozygous Familial Hypercholesterolemia
P3
Completed249RCT, Double-blindLMT (atorvastatin, simvastatin, or rosuvastatin), alirocumab, Placebo
NCT04101721
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
Retinopathy of Prematurity
P3
Completed127RCT, Open-labelaflibercept
NCT00327444
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms, Ascites
P2P3
Completed58RCT, Double-blindaflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
NCT03510715
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Hypercholesterolemia
P3
Completed18Open-labelAlirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin, Rosuvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids
NCT02396316
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
Glaucoma, Neovascular
P3
Completed54RCT, Double-blindAflibercept (Eylea, BAY 86-5321), Sham Injection
NCT03156621
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
P3
Completed69RCT, Double-blindAlirocumab, Placebo
NCT04004208
Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy
Retinopathy of Prematurity (ROP)
P3
Completed113RCT, Open-labelEylea (Aflibercept, BAY86-5321)
NCT03600818
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Polymyalgia Rheumatica
P3
Terminated118RCT, Double-blindSarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo, Prednisone
NCT01926782
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Hypercholesterolemia
P3
Completed803RCT, Double-blindPlacebo (for alirocumab), Alirocumab, Statin
NCT01521559
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
Branch Retinal Vein Occlusion
P3
Completed183RCT, Double-blindIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
NCT03304379
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Osteoarthritis, Knee, Osteoarthritis, Hip
P3
Completed1,650RCT, Double-blindFasinumab, Matching placebo
NCT01670721
Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
P3
Completed175Open-labelAFLIBERCEPT, Irinotecan, Fluorouracil, Leucovorin
NCT02373202
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Rheumatoid Arthritis
P3
Completed91RCT, Double-blindSarilumab, Sulfasalazine, Leflunomide, Bucillamine, Tacrolimus, Mizoribine
NCT01331681
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Diabetes Mellitus, Macular Edema
P3
Completed406RCT, Double-blindVEGF Trap-Eye (BAY86-5321), VEGF Trap-Eye (BAY86-5321)
NCT06602739
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
Allergic Conjunctivitis
P3
Completed54RCT, Double-blindREGN5713, REGN5715, Placebo
NCT02612454
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Atopic Dermatitis
P3
Completed880Open-labelDupilumab
NCT04701983
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
P3
Completed1,127RCT, Double-blindItepekimab SAR440340, Placebo
NCT03600805
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Giant Cell Arteritis
P3
Terminated83RCT, Double-blindSarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo
NCT03620747
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Asthma
P3
Completed393Open-labelDupilumab SAR231893 (REGN668)
NCT04183335
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Neurodermatitis
P3
Completed151RCT, Double-blindDupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
NCT04425629
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
COVID-19
P3
Terminated10,078Open-labelcasirivimab+imdevimab combination therapy
NCT03409744
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
P3
Completed116Open-labelevinacumab
NCT02326220
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Heterozygous Familial Hypercholesterolemia
P3
Completed62RCT, Double-blindPlacebo, Alirocumab
NCT05850520
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Macular Edema Secondary to Retinal Vein Occlusion
P3
Completed892RCT, Double-blindAflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham
NCT00519285
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Prostatic Neoplasms, Neoplasm Metastasis
P3
Completed1,224RCT, Double-blindAflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
NCT01764997
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Rheumatoid Arthritis
P3
Terminated776RCT, Double-blindSarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
NCT01949311
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
Atopic Dermatitis
P3
Completed2,733Open-labelDupilumab
NCT04452318
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Healthy Participants
P3
Completed3,303RCT, Double-blindREGN10933 + REGN10987, Placebo
NCT04423718
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Neovascular Age-Related Macular Degeneration
P3
Completed1,011RCT, Double-blindAflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
NCT01909791
Treatment for CI-DME in Eyes With Very Good VA Study
Diabetic Macular Edema
P3
Completed702RCT, Single-blindPrompt aflibercept, Deferred aflibercept
NCT02634333
Anti-VEGF Treatment for Prevention of PDR/DME
Diabetic Retinopathy, Diabetic Macular Edema
P3
Completed399RCT, Double-blindPrompt aflibercept, Deferred aflibercept
NCT04315298
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
COVID-19
P2P3
Completed1,912RCT, Double-blindSarilumab, Placebo
NCT01661270
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
Colorectal Cancer Metastatic
P3
Completed332RCT, Double-blindAflibercept, Placebo
NCT03633617
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
P3
Completed321RCT, Double-blindDupilumab, Placebo
NCT03257267
Study of Cemiplimab in Adults With Cervical Cancer
Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
P3
Completed608RCT, Open-labelCemiplimab, Investigator Choice (IC) Chemotherapy
NCT03345914
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
Dermatitis, Atopic
P3
Completed367RCT, Double-blindDupilumab, Matching Placebo
NCT06208306
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Chronic Obstructive Pulmonary Disease
P3
Completed669RCT, Double-blindItepekimab (SAR440340), Placebo
NCT04015180
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
Retinopathy of Prematurity (ROP)
P3
Completed100Open-labelEylea (Aflibercept, BAY86-5321)
NCT02948959
Evaluation of Dupilumab in Children With Uncontrolled Asthma
Asthma
P3
Completed408RCT, Double-blindDupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies
NCT00637377
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Macular Degeneration
P3
Completed1,240RCT, Double-blindRanibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
NCT02057250
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
RA
P3
Completed217RCT, Open-labelSarilumab, Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
NCT01459796
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Gout
P3
Terminated220RCT, Double-blindRilonacept, Placebo, Allopurinol
NCT03930732
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Chronic Obstructive Pulmonary Disease
P3
Completed939RCT, Double-blindDupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
NCT01709578
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Rheumatoid Arthritis
P3
Completed546RCT, Double-blindSarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
NCT02585778
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Hypercholesterolaemia
P3
Completed517RCT, Double-blindAlirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
NCT03161093
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Osteoarthritis, Knee, Osteoarthritis, Hip
P3
Completed3,307RCT, Double-blindFasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo
NCT02289963
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Hypercholesterolemia
P3
Completed199RCT, Double-blindPlacebo (for Alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
NCT06687967
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
Lichen Simplex Chronicus
P3
Completed142RCT, Double-blindDupilumab, Placebo
NCT01249664
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
Myopia, Pathological
P3
Completed122RCT, Double-blindVEGF Trap-Eye (BAY86-5321)
NCT04456673
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Chronic Obstructive Pulmonary Disease
P3
Completed935RCT, Double-blindDupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
NCT04206553
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Bullous Pemphigoid
P2P3
Completed106RCT, Double-blinddupilumab, Matching Placebo, Oral corticosteroids (OCS)
NCT01730053
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
Hypercholesterolemia
P3
Completed305RCT, Double-blindAlirocumab, Rosuvastatin, Ezetimibe, Placebo
NCT01644188
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Hypercholesterolemia
P3
Completed720RCT, Double-blindAlirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
NCT01512966
Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)
Macular Edema
P3
Completed73Open-labelVEGF Trap-Eye (BAY86-5321)
NCT07484230
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
P3
Withdrawn—RCT, Double-blindItepekimab (SAR440340), Placebo
NCT01571284
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Colorectal Cancer Metastatic
P3
Completed781Open-labelAFLIBERCEPT AVE0005, FOLFIRI
NCT02293902
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Rheumatoid Arthritis
P3
Completed243RCT, Double-blindSarilumab SAR153191 (REGN88), Methotrexate, Folic acid
NCT02277743
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis, Atopic
P3
Completed671RCT, Double-blindDupilumab, Placebo (for Dupilumab)
NCT02121210
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
P3
Completed132RCT, Open-labelsarilumab SAR153191 (REGN88)
NCT02755649
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
Atopic Dermatitis
P3
Completed325RCT, Double-blindDupilumab, Matching Placebo
NCT04751487
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
P3
Completed1,234RCT, Double-blindItepekimab SAR440340, Placebo
NCT03912259
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
P3
Completed165RCT, Double-blindDupilumab, Placebo, Emollient (moisturizer)
NCT03054428
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic
P3
Completed251RCT, Double-blindDupilumab, Placebo
NCT04202679
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
P3
Completed160RCT, Double-blindDupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
NCT01012973
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
P3
Completed177RCT, Double-blindAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
NCT01617655
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
Hypercholesterolaemia
P3
Completed107RCT, Double-blindAlirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
NCT04684524
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
Allergic Fungal Rhinosinusitis
P3
Completed62RCT, Double-blindDupilumab SAR231893, Placebo
NCT04981717
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
Allergic Rhinitis Due to Cat Allergy
P3
Terminated446RCT, Double-blindREGN1908-1909, Matching Placebo
NCT03088540
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell
P3
Completed712RCT, Open-labelPemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab
NCT03515629
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Non-small Cell Lung Cancer
P3
Terminated5RCT, Open-labelREGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
NCT07309432
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
Allergic Conjunctivitis
P3
Terminated24RCT, Double-blindREGN5713, REGN5715, Placebo
NCT02584504
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Hypercholesterolemia
P3
Completed163RCT, Double-blindAlirocumab, Placebo, Atorvastatin, Non-statin Lipid-Modifying Therapy
NCT01709513
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
Hypercholesterolemia
P3
Completed314RCT, Double-blindAtorvastatin, Ezetimibe, Alirocumab, Placebo
NCT06687980
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
Lichen Simplex Chronicus
P3
Completed138RCT, Double-blindDupilumab, Placebo
NCT03067844
Vascular Effects of Alirocumab in Acute MI-Patients
Coronary Vessel, Coronary Circulation
P3
Completed294RCT, Double-blindAlirocumab
NCT02395133
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
Atopic Dermatitis
P3
Completed422RCT, Double-blindDupilumab, Placebo
NCT02912468
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
P3
Completed276RCT, Double-blindDupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
NCT03782532
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
Asthma
P3
Completed486RCT, Double-blindDupilumab SAR231893, Placebo, Asthma Controller Therapies (include prednisone/prednisolone), Asthma Reliever Therapies
NCT01146652
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Rheumatoid Arthritis
P3
Completed2,023Open-labelSAR153191 (REGN88)
NCT03510884
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Hypercholesterolaemia
P3
Completed153RCT, Double-blindAlirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
NCT01363440
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
Diabetic Macular Edema
P3
Completed466RCT, Double-blindIntravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
NCT03346434
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
Dermatitis, Atopic
P2P3
Completed202Open-labelDupilumab, Matching placebo
NCT04327388
Sarilumab COVID-19
Corona Virus Infection
P3
Completed420RCT, Double-blindSarilumab SAR153191, Placebo
NCT07559513
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva, FOP
P3
Not Yet Recruiting18Open-labelgaretosmab
NCT07919899
Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation
Dermatitis Atopic
P3
Not Yet Recruiting150RCT, Open-labelDupilumab coformulated with berahyaluronidase alfa, Dupilumab
NCT00509795
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Macular Degeneration
P3
Completed1,217RCT, Double-blindranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321)
NCT03409614
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Non-small Cell Lung Cancer
P3
Completed789RCT, Double-blindREGN2810, REGN2810/chemo/ipi, Placebo
NCT05989126
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
P3
Completed35Open-labelaflibercept 8 mg PFS
NCT02476006
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Hypercholesterolemia
P3
Completed998Open-labelALIROCUMAB SAR236553 (REGN727), placebo (for injection training only), ezetimibe, atorvastatin, rosuvastatin, simvastatin
NCT03399786
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
P3
Completed65RCT, Double-blindevinacumab, Placebo
NCT03682770
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Peanut Allergy
P2
Completed148RCT, Double-blindDupilumab, Placebo matching dupilumab, AR101
NCT03294083
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
Renal Cell Carcinoma
P1P2
Completed95RCT, Open-labelPexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
NCT04502966
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
Allergic Rhinoconjunctivitis, Grass Pollen Allergy
P2
Completed199RCT, Double-blindDupixent®, Grazax®, Dupixent® Placebo, Grazax® Placebo
NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Solid Tumor, Adult, Advanced Solid Tumor
P1P2
Completed98Open-labelSNS-101 (anti-VISTA), Cemiplimab
NCT01988246
Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
P1P2
Completed30RCT, Single-blindAflibercept, Sham
NCT02085005
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
P2
Withdrawn—Open-labelCapecitabine, Aflibercept AVE0005, Oxaliplatin SR96669
NCT03430063
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Advanced Non-Small Cell Lung Carcinoma
P2
Terminated28RCT, Open-labelSDREGN2810, SDREGN2810/ipi, HDREGN2810
NCT06454630
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
Venous Thromboembolism
P2
Completed179RCT, Open-labelREGN7508, Enoxaparin
NCT07863024
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
Advanced Solid Tumors
P1P2
Not Yet Recruiting320RCT, Open-labelREGN13089-M404-M2980
NCT04242173
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
P2
Terminated3Open-labelCemiplimab-Rwlc
NCT06122922
Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
Pulmonary Artery Hypertension
P2
Withdrawn—Open-labelHyperpolarized Xe129
NCT06848088
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Melanoma
P2
By Invite48Open-labelFianlimab+cemiplimab
NCT03669718
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
P2
Unknown194RCT, Double-blindISA101b, Cemiplimab
NCT03738423
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
P2
Terminated129RCT, Double-blindREGN3500, REGN3500-Matching Placebo
NCT03787095
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
HIV Infections
P1P2
Terminated5RCT, Double-blindCemiplimab, Placebo
NCT04373083
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Hodgkin Lymphoma
P2
Withdrawn—RCT, Open-labelCemiplimab
NCT02379052
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
P2
Completed47RCT, Double-blindDupilumab, Placebo
NCT07887750
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
Diffuse Large B-Cell Lymphoma (DLBCL)
P1P2
Not Yet Recruiting36Open-labelREGN9220, Odronextamab
NCT04256759
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Pruritus
P2
Completed9Open-labelDupilumab 300Mg Solution for Injection
NCT06237309
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
Heart Failure
P2
Terminated89RCT, Double-blindREGN5381, Placebo
NCT03949673
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
Osteoarthritis, Knee, Osteoarthritis, Hip
P2
Terminated23Open-labelFasinumab, Naproxen, Diclofenac, Celecoxib, Placebo
NCT02045030
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
P2
Terminated14Open-labelaflibercept + FOLFIRI
NCT04888507
Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
Paroxysmal Nocturnal Hemoglobinuria
P2
Completed6Open-labelPozelimab, Cemdisiran
NCT06571708
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
P2
Terminated1RCT, Open-labelGemcitabine, Cisplatin, Cemiplimab, Fianlimab
NCT02573233
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
Asthma
P2
Completed42RCT, Double-blindPlacebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
NCT01061723
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
P2
Completed301RCT, Double-blindSarilumab, Placebo
NCT03956550
A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
Osteoarthritis of the Knee, Pain
P2
Terminated259RCT, Double-blindREGN5069, Matching Placebo
NCT01859988
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
P2
Completed380RCT, Double-blindDupilumab, Placebo
NCT02713204
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Neovascular Age-Related Macular Degeneration
P2
Completed365RCT, Double-blindREGN910-3, Intravitreal Aflibercept Injection (IAI)
NCT01920893
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Nasal Polyps
P2
Completed60RCT, Double-blindPlacebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray
NCT05088460
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
Familial Partial Lipodystrophy, Metabolic Abnormalities
P2
Terminated20RCT, Double-blindREGN4461, Matching Placebo
NCT02265952
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
P2
Completed9Open-labelREGN1500 250 mg SC/15 mg/kg IV/450 mg SC
NCT07836101
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
Any Advanced Solid Tumors
P2
Not Yet Recruiting41Open-labelSarilumab, ICI Therapy
NCT04083534
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
P1P2
Completed43Open-labelREGN5459
NCT05202288
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Ebola Virus Disease
P2
Not Yet Recruiting132RCT, Open-labelErvebo, Inmazeb
NCT00396591
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms
P2
Completed16Open-labelAflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
NCT04339062
Cemiplimab in AlloSCT/SOT Recipients With CSCC
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
P1P2
Completed12Open-labelCemiplimab, Everolimus, Sirolimus, Prednisone
NCT04362501
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Chronic Sinusitis
P2
Completed33RCT, Double-blinddupilumab, placebo
NCT07850921
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
Metastatic Castration-Resistant Prostate Cancer, mCRPC
P1P2
Not Yet Recruiting192Open-labelREGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
NCT07567469
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
P1P2
Not Yet Recruiting120RCT, Open-labelCemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
NCT04588948
A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema
Diabetic Macular Edema
P2
Withdrawn—Open-labelIntravitreal Aflibercept
NCT01955629
Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
Colorectal Cancer Metastatic
P1P2
Terminated4Open-labelAflibercept AVE0005, Oxaliplatin, Capecitabine
NCT01604824
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
Hypercholesterolemia
P2
Completed23RCT, Double-blindAlirocumab, Placebo
NCT01288469
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
Hypercholesterolemia
P2
Completed92RCT, Double-blindAlirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
NCT04296864
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
Atopic Keratoconjunctivitis
P2
Unknown42RCT, Double-blindDupilumab
NCT03678545
Dupilumab in Eosinophilic Gastritis
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
P2
Completed41RCT, Double-blindDupilumab (blinded), Placebo (blinded)
NCT02890992
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Hypercholesterolaemia
P2
Completed42Open-labelalirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
NCT07808138
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
Non Small Cell Lung Cancer, Immunotherapy
P2
Not Yet Recruiting30Open-labelCemiplimab 350 mg IV
NCT03886493
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Prostate Cancer
P2
Terminated7Open-labelDupilumab
NCT04154943
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
P2
Completed79Open-labelCemiplimab
NCT07832370
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
Prion Disease
P1P2
Not Yet Recruiting60Open-labelALN-6457
NCT00609544
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Chronic Kidney Disease, Anemia
P2
Withdrawn—RCT, Double-blindRilonacept
NCT07414992
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Bladder Urothelial Carcinoma
P2
Withdrawn—Open-labelCemiplimab, Cemiplimab and Fianlimab
NCT04852978
COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
Healthy, Chronic Stable Illness
P2
Completed295RCT, Open-labelcasirivimab+imdevimab, Moderna mRNA-1273 vaccine
NCT03793608
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Peanut Allergy
P2
Completed25Open-labelDupilumab
NCT02171416
Cold Contact Urticaria Treatment With Rilonacept
Cold Contact Urticaria
P2
Completed20RCT, Double-blindRilonacept, Placebo
NCT01538719
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma, Systemic Sclerosis
P1P2
Completed24RCT, Double-blindRilonacept
NCT01266876
Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
Hypercholesterolemia
P2
Completed77RCT, Double-blindAlirocumab, Placebo
NCT04159415
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
P2
Completed16RCT, Double-blindPlacebo, Low-Dose REGN4461, High-dose REGN4461
NCT02712008
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
P2
Completed302RCT, Double-blindREGN910-3, Intravitreal Aflibercept Injection (IAI)
NCT04398524
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
Squamous Cell Carcinoma of the Oropharynx
P2
Unknown65Open-labelISA101b
NCT03558997
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
Allergic Rhinitis
P2
Completed103RCT, Double-blindDupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT
NCT04148352
Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
Allergies Food Milk
P2
Terminated33RCT, Double-blindDupilumab
NCT03838731
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
Cat Allergy, Mild Asthma
P2
Completed56RCT, Double-blindREGN1908-1909, Placebo
NCT03387852
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Asthma
P2
Completed296RCT, Double-blindSAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
NCT03712904
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Uveal Melanoma
P2
Terminated3RCT, Open-labelZiv-Aflibercept
NCT02776735
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Juvenile Idiopathic Arthritis
P2
Completed102Open-labelSarilumab
NCT03085784
Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
Radiation Retinopathy
P2
Unknown40RCT, Open-labelAflibercept
NCT04992273
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
COVID-19
P2
Terminated7Open-labelcasirivimab+imdevimab
NCT00284141
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
Pulmonary Diseases, Neoplasms, Lung
P2
Completed98Open-labelAflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
NCT01288443
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Hypercholesterolemia
P2
Completed183RCT, Double-blindAlirocumab, Placebo (for alirocumab), Atorvastatin
NCT07891182
VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study
Glaucoma
P2
Not Yet Recruiting100RCT, Open-labelAflibercept Injection
NCT06384820
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
Cutaneous Squamous Cell Carcinoma
P2
Withdrawn—RCT, Open-labelcemiplimab, fianlimab
NCT01312961
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Asthma
P2
Completed104RCT, Double-blindDupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
NCT04646005
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Cervical Cancer
P2
Completed113Open-labelCemiplimab, ISA101b
NCT01001923
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
Abdominal Pain Upper
P2
Terminated15RCT, Double-blindREGN475/SAR164877, Placebo (for REGN475/SAR164877)
NCT03175367
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
Hypercholesterolemia
P2
Completed272RCT, Double-blindEvinacumab, Matching placebo
NCT02418754
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
Neovascular Age-Related Macular Degeneration
P2
Terminated505RCT, Double-blindREGN2176-3, Intravitreal Aflibercept Injection (IAI)
NCT01812707
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
Hypercholesterolemia
P2
Completed100RCT, Double-blindAlirocumab, Placebo (for alirocumab), Atorvastatin
NCT01118728
Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
P2
Terminated223Open-labelSarilumab
NCT03736967
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
P2
Terminated206RCT, Double-blindREGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo
NCT04126317
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Neovascular (Wet) Age-Related Macular Degeneration
P2
Completed106RCT, Single-blindaflibercept, High-dose aflibercept
NCT01882868
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Colorectal Cancer Metastatic
P2
Completed62Open-labelAflibercept, Levofolinate, Irinotecan, 5-FU
NCT06833190
REGN5381 in Adult Participants With Uncontrolled Hypertension
Uncontrolled Hypertension
P2
Terminated34RCT, Double-blindREGN5381, Placebo
NCT04311606
Anti-VEGF Therapy for Acute Thyroid Eye Disease
Thyroid Eye Disease
P2
Terminated8RCT, Double-blindSub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
NCT02210780
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
Atopic Dermatitis
P2
Completed194RCT, Double-blindDupilumab, Placebo
NCT00789477
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
Diabetic Macular Edema
P2
Completed221RCT, Double-blindIntravitreal Aflibercept Injection
NCT01724554
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
P1P2
Completed24RCT, Open-labelIntravitreal Aflibercept Injection
NCT07620548
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas
Glioblastoma, Glioblastoma, IDH-wildtype
P2
Not Yet Recruiting99RCT, Open-labelCemiplimab, Chemotherapy
NCT06691113
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
Chronic Rhinosinusitis Without Nasal Polyps
P2
Completed66RCT, Double-blindItepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
NCT00320788
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
Macular Degeneration
P2
Completed159RCT, Double-blindaflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321)
NCT06373146
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Obesity
P2
Completed392RCT, Double-blindTirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo
NCT01710332
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
P2
Completed12RCT, Open-labelIntravitreal Aflibercept Injection
NCT06052852
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
P1
Terminated17Open-labelBDC-3042, Cemiplimab
NCT04826393
ASP8374 + Cemiplimab in Recurrent Glioma
Glioblastoma, Recurrent Glioblastoma
P1
Completed14RCT, Open-labelASP8374, cemiplimab
NCT00082823
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Cancer
P1
Completed25Open-labelziv-aflibercept
NCT03396861
Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept
Irvine-Gass Syndrome
P1
Terminated1Open-labelAflibercept
NCT02107872
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Metabolic Disorders
P1
Completed55RCT, Double-blindREGN1500, placebo
NCT03438318
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
P1
Completed29Open-labelCMP-001, Atezolizumab
NCT06137482
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants
Healthy Volunteers
P1
Completed56RCT, Double-blindREGN13335, Matching Placebo
NCT02943239
Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
Healthy Volunteers
P1
Completed82RCT, Double-blindREGN1033, REGN2477
NCT02061865
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Neovascular Wet Age-related Macular Degeneration (AMD)
P1
Completed12Open-labelREGN2176-3
NCT00545246
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
Neoplasms
P1
Completed12Open-labelaflibercept (AVE0005), docetaxel
NCT02383212
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Advanced Cancer, Advanced Malignancies
P1
Completed398Open-labelCemiplimab, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed
NCT01959971
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
Hypercholesterolemia
P1
Completed20Single-blindalirocumab, Placebo
NCT02744287
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
P1
Terminated52Open-labelBPX-601, Rimiducid
NCT00871559
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
Advanced Solid Malignancies
P1
Completed83Open-labelREGN421(SAR153192)
NCT06970405
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
Obesity
P1
Withdrawn—RCT, Double-blindGaretosmab, Matching Placebo
NCT00383370
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
Neovascular Age Related Macular Degeneration
P1
Completed20RCT, Double-blindVEGF Trap, VEGF Trap
NCT03746704
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
Advanced PD-L1 Positive Malignancies
P1
Terminated2Open-label89Zr˗DFO˗REGN3504
NCT01723735
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
Hypercholesterolemia
P1
Completed79RCT, Open-labelAlirocumab, Ezetimibe, Ezetimibe Placebo, Fenofibrate
NCT03491904
To Assess the Patients' Ability to Self-Administer Fasinumab
Osteoarthritis, Knee, Osteoarthritis, Hip
P1
Completed100RCT, Open-labelFasinumab AI, Fasinumab PFS
NCT05157997
Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail
COVID-19, Organ Transplant
P1
Withdrawn—Open-labelCasirivimab and Imdevimab Antibody Cocktail
NCT03530514
A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers
Healthy Volunteers
P1
Completed113RCT, Double-blindREGN4461, Placebo
NCT06444178
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
Healthy Volunteers
P1
Completed224RCT, Open-labelAspirin, REGN9933, REGN7508, Rivaroxaban
NCT02520245
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Advanced Malignancies
P1
Withdrawn—Open-labelREGN2810
NCT04465487
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Squamous Cell Carcinoma of Head and Neck
P1
Terminated38Open-labelREGN6569, Cemiplimab
NCT01922661
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
Allergy
P1
Completed24RCT, Double-blindREGN1908-1909
NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
P1
Completed200Open-labelOdronextamab multiple dose levels, Odronextamab multiple dose levels
NCT05291546
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
Healthy Volunteers
P1
Completed93RCT, Double-blindREGN9035, REGN5381
NCT03112577
Study of REGN3500 and Dupilumab in Patients With Asthma
Asthma, Allergic
P1
Completed32RCT, Double-blindREGN3500, Dupilumab, Placebo, Fluticasone propionate
NCT02204683
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
Neovascular Macular Degeneration
P1
Completed5Open-labelAflibercept
NCT05976386
Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults
Healthy Volunteers
P1
Completed182RCT, Open-labelDupilumab (SAR231893)
NCT01785329
Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects
Hypercholesterolemia
P1
Completed60RCT, Open-labelalirocumab SAR236553 (REGN727)
NCT05976373
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
Healthy Volunteers
P1
Completed38RCT, Open-labelDupilumab (SAR231893)
NCT01910220
Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
Healthy Volunteers
P1
Completed125RCT, Double-blindREGN1033 (SAR391786)
NCT02828397
Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
Healthy Volunteers
P1
Completed28RCT, Open-labelREGN2222
NCT05970718
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
Healthy Volunteers
P1
Completed80RCT, Double-blindREGN7544, Matching Placebo
NCT02999711
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
Asthma, Moderate Asthma
P1
Completed23RCT, Double-blindREGN3500, Placebo
NCT00921661
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms, Neoplasm Metastasis
P1
Completed16Open-labelAVE0005 (aflibercept)
NCT01259323
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
Dermatitis
P1
Completed30RCT, Double-blindREGN668, REGN668, REGN668
NCT03005782
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Malignancies
P1
Completed333Open-labelREGN3767, cemiplimab
NCT01537653
Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects
Healthy
P1
Completed32RCT, Double-blindSAR231893 (REGN668), placebo
NCT05505448
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
Healthy
P1
Completed48RCT, Double-blindREGN14284, Matching Placebo
NCT04982224
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Advanced NSCLC
P1
Terminated30Open-labelREGN5093-M114, Cemiplimab
NCT01026519
A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
P1
Completed32RCT, Double-blindREGN88
NCT01443650
Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Hypercholesterolemia
P1
Completed36RCT, Double-blindalirocumab SAR236553 (REGN727)
NCT07876505
Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations
Healthy Volunteers
P1
Not Yet Recruiting80RCT, Open-labelCenvacibart
NCT04940364
A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers
Healthy
P1
Completed30Open-labelPozelimab, Cemdisiran
NCT03146416
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
Healthy Volunteers
P1
Completed96RCT, Double-blindEvinacumab, Placebo
NCT02284425
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
P1
Terminated72RCT, Double-blindREGN1193, Placebo
NCT00644124
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
Lymphoma, Non-Hodgkin
P1
Completed25Open-labelaflibercept
NCT01161082
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
Hypercholesterolemia
P1
Completed72RCT, Double-blindREGN727(SAR236553)
NCT03002376
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Melanoma
P1
Completed47Open-labelREGN2810
NCT02516618
Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects
Healthy Volunteers
P1
Completed72RCT, Double-blindFasinumab, Placebo
NCT06024408
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
P1
Completed9RCT, Double-blindALN-PNP, Placebo
NCT02958436
A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects
Healthy Volunteers
P1
Completed40RCT, Double-blindREGN3500, Placebo
NCT06669234
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
Healthy Volunteer
P1
Completed56RCT, Double-blindALN-F1202, Matching Placebo
NCT00083213
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Cancer
P1
Completed25Open-labelziv-aflibercept
NCT03115996
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers
Healthy Volunteers
P1
Completed56RCT, Double-blindREGN3918, Placebo
NCT05181683
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
Healthy, Chronic Stable Illness
P1
Completed45RCT, Open-labelCasirivimab+Imdevimab
NCT03645746
Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers
Healthy Volunteer
P1
Completed56RCT, Double-blindREGN5069, Placebo
NCT02127801
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
Allergy
P1
Completed74RCT, Double-blindREGN1908-1909, placebo
NCT01579760
Intravitreal Aflibercept Injection for Radiation Retinopathy
Radiation Retinopathy, Macular Edema
P1
Completed9RCT, Single-blindAflibercept every 2 months, Aflibercept monthly
NCT01209793
Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers
Healthy
P1
Completed40RCT, Double-blindREGN846
NCT04616105
Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers
Healthy Volunteer
P1
Terminated19RCT, Double-blindREGN6490, Placebo
NCT00036946
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
P1
Completed——ziv-aflibercept
NCT04506645
Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans
Healthy
P1
Completed90RCT, Double-blindREGN5381
NCT02870400
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477
Healthy Volunteers
P1
Completed41RCT, Double-blindREGN2477, Placebo
NCT05064085
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
Hormone Receptor-positive Breast Cancer
P1
Completed13Open-labelCemiplimab, Capecitabine
NCT07861152
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
Graves' Disease
P1
Not Yet Recruiting45RCT, Double-blindREGN24493, Placebo
NCT01688960
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Solid Tumors
P1
Completed48Open-labelnesvacumab (REGN910/ SAR307746), nesvacumab (REGN910/ SAR307746), nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept), aflibercept (ziv-aflibercept)
NCT01537640
Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects
Healthy
P1
Completed30RCT, Double-blindSAR231893 (REGN668) DP1, SAR231893 (REGN668) DP2
NCT05169489
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Diffuse Large B Cell Lymphoma (DLBCL)
P1
Terminated15Open-labelbbT369
NCT03969849
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
Healthy Volunteers, Birch Pollen Allergy
P1
Completed96RCT, Double-blindREGN5713-5714-5715, Matching placebo
NCT01933763
An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
Healthy Volunteers
P1
Completed56RCT, Double-blindREGN1193
NCT00856310
A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
Healthy
P1
Completed56RCT, Double-blindREGN475 (SAR164877)
NCT02121080
Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers
Healthy Volunteers
P1
Completed132RCT, Double-blindREGN2222(SAR438584), placebo
NCT04409080
REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
Severe Aplastic Anemia (SAA)
P1
Terminated17Open-labelREGN7257
NCT01850680
Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
P1
Completed61RCT, Double-blindsarilumab SAR153191 (REGN88), placebo, methotrexate, folic acid
NCT01328522
Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
P1
Completed32RCT, Single-blindSAR153191 (REGN88)
NCT01448317
Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers
Hypercholesterolemia
P1
Completed32RCT, Double-blindAlirocumab (Solution), Alirocumab (Lyophilized formulation), Placebo (Solution), Placebo (Lyophilized formulation)
NCT05293678
Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19
Healthy
P1
Completed104RCT, Double-blindREGN15160 (IV), Matching Placebo (IV), REGN15160 (SC), Matching Placebo (SC)
NCT01868360
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Corneal Neovascularization
P1
Terminated2RCT, Open-labelSubconjunctival aflibercept
NCT05054348
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
Solid Tumor, Adult
P1
Completed91Open-labelIO-108, IO-108 + pembrolizumab combination therapy, IO-108 + cemiplimab combination therapy
NCT01197391
Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers
Healthy
P1
Completed48RCT, Double-blindREGN728
NCT01026597
Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers
Healthy
P1
Completed40RCT, Double-blindREGN727, Placebo
NCT04616079
Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers
Healthy Volunteer
P1
Terminated57RCT, Double-blindREGN6490, Placebo
NCT02647086
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
Atopic Dermatitis
P1
Completed14Open-labelDupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol
NCT02017639
Sarilumab Effect on the Pharmacokinetics of Simvastatin
Rheumatoid Arthritis
P1
Completed19Open-labelsarilumab SAR153191 (REGN88), simvastatin
NCT05013723
Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome
Post-acute COVID-19 (PACS), or "long COVID" Syndrome
Completed260——
NCT03507374
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Stroke, Intracranial Atherosclerosis
Early P1
Terminated20RCT, Double-blindAlirocumab, Placebo
NCT05203380
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Completed45—dupilumab
NCT01773954
Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
Age-Related Macular Degeneration, Macular Degeneration
N/A
Completed40Open-labelIntravitreal Aflibercept Injection
NCT06064656
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva (FOP)
Completed131——
NCT05991323
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Prurigo Nodularis
Completed110—Dupilumab
NCT05423327
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Steatohepatitis (NASH)
N/A
Terminated5,311Open-label—
NCT03576690
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Ebola Virus Disease
AVAILABLE——REGN3470-3471-3479
NCT01783925
Eylea Post Marketing Surveillance(PMS)
Macular Degeneration
Completed3,206—Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT02811692
Study for Collection of Aflibercept Data in Routine Practice
Eye Diseases
Completed425—Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT04550962
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
Asthma
Completed376—Dupilumab SAR231893
NCT03278262
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
Wet Macular Degeneration
Completed2,312—Aflibercept (Eylea, BAY86-5321)
NCT07316114
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Terminated1—Dupilumab
NCT05906706
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
Bullous Pemphigoid
APPROVED_FOR_MARKETING——dupilumab
NCT03836105
CemiplimAb Survivorship Epidemiology
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Completed287—cemiplimab
NCT06019481
A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations
Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene
Withdrawn———
NCT01771081
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
Ophthalmology, Macular Edema
Completed911—Ranibizumab (or other DME treatment)
NCT01418781
CLinical Prediction Rule Score in Veterans
Gout
Withdrawn———
NCT01714115
Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Retinal Hemangioma
NO_LONGER_AVAILABLE——Aflibercept
NCT04617535
Compassionate Use of REGN-COV2 for the Treatment of COVID-19
COVID-19
NO_LONGER_AVAILABLE——REGN10933+REGN10987 combination therapy
NCT04722068
Regeneron 1331 Kinetics Sub-Study HoFH
Hypercholesterolemia, Familial
N/A
Completed4Open-label—
NCT05232110
Compassionate Use of Pozelimab
CD55-deficient Protein-losing Enteropathy
APPROVED_FOR_MARKETING——Pozelimab
NCT05338879
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma
Relapsed/Refractory Follicular Lymphoma
Completed247——
NCT06028594
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
NO_LONGER_AVAILABLE——Pozelimab, Cemdisiran
NCT05546957
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
Healthy Volunteer
N/A
Completed60RCT, Open-labelAspirin, rivaroxaban low dose, rivaroxaban high dose
NCT06631677
Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
Food Allergy
AVAILABLE——Dupilumab
NCT06500598
Compassionate Use of Evinacumab
Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG)
APPROVED_FOR_MARKETING——Evinacumab
NCT04173442
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Atopic Dermatitis (AD), Asthma
Completed581—dupilumab
NCT05870215
Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks
Asthma
Completed78——
NCT05619367
A Compassionate Use (CU) Program of Odronextamab
Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)
AVAILABLE——Odronextamab
NCT07105228
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
Retinal Vasculitis
Completed290,000—aflibercept 2mg
NCT02040220
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
Completed385—Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT06769412
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
Retinal Vasculitis
Completed550,000—aflibercept 2 mg
NCT02321241
Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD
Wet Macular Degeneration
Completed236—Aflibercept (EYLEA, BAY-86-5321)
NCT02645747
Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
Retinal Vein Occlusion
Completed126—Aflibercept (Eylea, BAY86-5321)
NCT03378219
An Observational Study on Sarilumab-exposed Pregnancies
Rheumatoid Arthritis -Exposure During Pregnancy
Completed113—Sarilumab SAR153191 (REGN88)
NCT05673967
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma (RRMM)
Completed62——
NCT05302297
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
Cancer/Squamous Cell Carcinoma of Skin
Completed305—Cemiplimab
NCT05164250
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Multiple Myeloma
APPROVED_FOR_MARKETING——REGN5458
NCT03382587
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
Wet Age-related Macular Degeneration
Completed163—Aflibercept (Eylea, BAY86-5321)
NCT03228693
Gene Expression and Biomarker Profiling of Keloid Skin
Keloid, Keloid of Ear Lobe
N/A
Completed48Open-label—
NCT06132191
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
APPROVED_FOR_MARKETING——Cemiplimab
NCT02585401
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Completed99—Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
NCT04287608
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
Conjunctivitis, Atopic Dermatitis
Completed50—dupilumab
NCT04287621
Registry of Asthma Patients Initiating DUPIXENT®
Asthma
Completed718—DUPIXENT®
NCT03411941
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
Macular Degeneration
Completed116—Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
NCT03051347
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
Atopic Dermatitis, Ichthyosis
N/A
Completed943Open-label—
NCT01756261
EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
Macular Degeneration
Completed757—Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT02541084
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
Wet Macular Degeneration
Completed72—Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
NCT04614571
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
Celiac Disease
N/A
Completed24Open-label—